Efficacy and Safety Outcomes Up to ~4 Years of Treatment With Filgotinib 200 mg Among Patients With Ulcerative Colitis: Results From the SELECTIONLTE Study.
出版信息
Gastroenterol Hepatol (N Y). 2023 Apr;19(4 Suppl 1):10-11.
Abstract
摘要
相似文献
1
Efficacy and Safety Outcomes Up to ~4 Years of Treatment With Filgotinib 200 mg Among Patients With Ulcerative Colitis: Results From the SELECTIONLTE Study.
Gastroenterol Hepatol (N Y). 2023 Apr;19(4 Suppl 1):10-11.
2
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Lancet. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3.
3
Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis.
J Crohns Colitis. 2022 Jun 24;16(5):835-844. doi: 10.1093/ecco-jcc/jjab206.
4
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial.
Intest Res. 2023 Jan;21(1):110-125. doi: 10.5217/ir.2021.00143. Epub 2022 Mar 11.
5
Filgotinib for moderately to severely active ulcerative colitis.
Expert Rev Gastroenterol Hepatol. 2022 Oct;16(10):927-940. doi: 10.1080/17474124.2022.2138857. Epub 2022 Nov 14.
6
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study.
J Crohns Colitis. 2023 Mar 18;17(2):211-220. doi: 10.1093/ecco-jcc/jjac122.
7
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161-170. doi: 10.1016/S2468-1253(21)00377-0. Epub 2021 Nov 29.
8
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial.
J Crohns Colitis. 2023 Jun 16;17(6):863-875. doi: 10.1093/ecco-jcc/jjad018.
9
Health Status, Quality of Life, Psychosocial Well-being, and Wearables Data of Patients With Active Ulcerative Colitis Receiving Filgotinib Therapy (FilgoColitis Study): Protocol for a Real-world Observational Study.
JMIR Res Protoc. 2023 May 8;12:e42574. doi: 10.2196/42574.
10
Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis.
Int J Clin Pharm. 2023 Apr;45(2):330-341. doi: 10.1007/s11096-022-01509-1. Epub 2022 Dec 9.
引用本文的文献
1
Small Molecules, Big Results: How JAK Inhibitors Have Transformed the Treatment of Patients with IBD.
Dig Dis Sci. 2025 Feb;70(2):469-477. doi: 10.1007/s10620-024-08792-0. Epub 2024 Dec 20.
2
Focus on Filgotinib in Rheumatoid Arthritis: A Trial-Based Review.
Mediterr J Rheumatol. 2024 Mar 30;35(Suppl 1):1-9. doi: 10.31138/mjr.281123.fof. eCollection 2024 Mar.
3
JAK inhibitors for inflammatory bowel disease: recent advances.
Frontline Gastroenterol. 2023 Sep 14;15(1):59-69. doi: 10.1136/flgastro-2023-102400. eCollection 2024 Jan.
本文引用的文献
1
Filgotinib for moderately to severely active ulcerative colitis.
Expert Rev Gastroenterol Hepatol. 2022 Oct;16(10):927-940. doi: 10.1080/17474124.2022.2138857. Epub 2022 Nov 14.
2
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
Lancet. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3.
Zotero 插件